APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biologics and Biosimilars Market Outlook and Growth Opportunities 2026

26 December 2025207 pages

Choose your research edition.

Industry ResearchBiologics and Biosimilars Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics and Biosimilars Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics and Biosimilars Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics and Biosimilars Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biologics and Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biologics and Biosimilars market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Pfizer, AbbVie, United Laboratory and Tonghua Dongbao, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Biologics and Biosimilars market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics and Biosimilars and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics and Biosimilars revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biologics and Biosimilars market.

Biologics and Biosimilars Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Pfizer

AbbVie

United Laboratory

Tonghua Dongbao

Sobi

Novo Nordisk

Kanghong Pharma

Innovent Biologics

Gan&Lee

Eli Lilly

Changchun High Tech

Celltrion

Biogen

Amgen

3SBIO

Biologics and Biosimilars Segment by Type

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Others

Biologics and Biosimilars Segment by Application

Hospital

Retail Pharmacy

Other

Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biologics and Biosimilars status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biologics and Biosimilars key companies, revenue, market share, and recent developments.

3. To split the Biologics and Biosimilars breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biologics and Biosimilars Industry Trends Table 2. Biologics and Biosimilars Industry Drivers Table 3. Biologics and Biosimilars Industry Opportunities and Challenges Table 4. Biologics and Biosimilars Industry Restraints Table 5. Global Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biologics and Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Biologics and Biosimilars Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biologics and Biosimilars Key Company Manufacturing Base & Headquarters Table 9. Global Biologics and Biosimilars Company, Product Type & Application Table 10. Global Biologics and Biosimilars Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Monoclonal Antibodies Table 15. Significant Companies of Interferon Table 16. Significant Companies of Insulin Table 17. Significant Companies of Vaccines Table 18. Significant Companies of Others Table 19. Global Biologics and Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Biologics and Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Biologics and Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Biologics and Biosimilars Sales Value Share by Type (2021-2026) Table 23. Global Biologics and Biosimilars Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Retail Pharmacy Table 26. Significant Companies of Other Table 27. Global Biologics and Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Biologics and Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Biologics and Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Biologics and Biosimilars Sales Value Share by Application (2021-2026) Table 31. Global Biologics and Biosimilars Sales Value Share by Application (2027-2032) Table 32. Global Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Biologics and Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Biologics and Biosimilars Sales Value Share by Region (2021-2026) Table 35. Global Biologics and Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Biologics and Biosimilars Sales Value Share by Region (2027-2032) Table 37. Global Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Biologics and Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Biologics and Biosimilars Sales Value Market Share by Country (2021-2026) Table 40. Global Biologics and Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Biologics and Biosimilars Sales Value Market Share by Country (2027-2032) Table 42. Sanofi Company Information Table 43. Sanofi Business Overview Table 44. Sanofi Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Sanofi Biologics and Biosimilars Product Portfolio Table 46. Sanofi Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Johnson & Johnson Biologics and Biosimilars Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. Novartis Company Information Table 53. Novartis Business Overview Table 54. Novartis Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Novartis Biologics and Biosimilars Product Portfolio Table 56. Novartis Recent Development Table 57. Merck Company Information Table 58. Merck Business Overview Table 59. Merck Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Merck Biologics and Biosimilars Product Portfolio Table 61. Merck Recent Development Table 62. Roche Company Information Table 63. Roche Business Overview Table 64. Roche Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Roche Biologics and Biosimilars Product Portfolio Table 66. Roche Recent Development Table 67. Pfizer Company Information Table 68. Pfizer Business Overview Table 69. Pfizer Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Pfizer Biologics and Biosimilars Product Portfolio Table 71. Pfizer Recent Development Table 72. AbbVie Company Information Table 73. AbbVie Business Overview Table 74. AbbVie Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. AbbVie Biologics and Biosimilars Product Portfolio Table 76. AbbVie Recent Development Table 77. United Laboratory Company Information Table 78. United Laboratory Business Overview Table 79. United Laboratory Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. United Laboratory Biologics and Biosimilars Product Portfolio Table 81. United Laboratory Recent Development Table 82. Tonghua Dongbao Company Information Table 83. Tonghua Dongbao Business Overview Table 84. Tonghua Dongbao Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Tonghua Dongbao Biologics and Biosimilars Product Portfolio Table 86. Tonghua Dongbao Recent Development Table 87. Sobi Company Information Table 88. Sobi Business Overview Table 89. Sobi Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Sobi Biologics and Biosimilars Product Portfolio Table 91. Sobi Recent Development Table 92. Novo Nordisk Company Information Table 93. Novo Nordisk Business Overview Table 94. Novo Nordisk Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Novo Nordisk Biologics and Biosimilars Product Portfolio Table 96. Novo Nordisk Recent Development Table 97. Kanghong Pharma Company Information Table 98. Kanghong Pharma Business Overview Table 99. Kanghong Pharma Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Kanghong Pharma Biologics and Biosimilars Product Portfolio Table 101. Kanghong Pharma Recent Development Table 102. Innovent Biologics Company Information Table 103. Innovent Biologics Business Overview Table 104. Innovent Biologics Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Innovent Biologics Biologics and Biosimilars Product Portfolio Table 106. Innovent Biologics Recent Development Table 107. Gan&Lee Company Information Table 108. Gan&Lee Business Overview Table 109. Gan&Lee Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Gan&Lee Biologics and Biosimilars Product Portfolio Table 111. Gan&Lee Recent Development Table 112. Eli Lilly Company Information Table 113. Eli Lilly Business Overview Table 114. Eli Lilly Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Eli Lilly Biologics and Biosimilars Product Portfolio Table 116. Eli Lilly Recent Development Table 117. Changchun High Tech Company Information Table 118. Changchun High Tech Business Overview Table 119. Changchun High Tech Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Changchun High Tech Biologics and Biosimilars Product Portfolio Table 121. Changchun High Tech Recent Development Table 122. Celltrion Company Information Table 123. Celltrion Business Overview Table 124. Celltrion Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Celltrion Biologics and Biosimilars Product Portfolio Table 126. Celltrion Recent Development Table 127. Biogen Company Information Table 128. Biogen Business Overview Table 129. Biogen Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Biogen Biologics and Biosimilars Product Portfolio Table 131. Biogen Recent Development Table 132. Amgen Company Information Table 133. Amgen Business Overview Table 134. Amgen Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Amgen Biologics and Biosimilars Product Portfolio Table 136. Amgen Recent Development Table 137. 3SBIO Company Information Table 138. 3SBIO Business Overview Table 139. 3SBIO Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. 3SBIO Biologics and Biosimilars Product Portfolio Table 141. 3SBIO Recent Development Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Biologics and Biosimilars Product Image Figure 2. Global Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics and Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Monoclonal Antibodies Image Figure 8. Interferon Image Figure 9. Insulin Image Figure 10. Vaccines Image Figure 11. Others Image Figure 12. Global Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Biologics and Biosimilars Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Retail Pharmacy Image Figure 17. Other Image Figure 18. Global Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Biologics and Biosimilars Sales Value Share by Application (2021-2032) Figure 21. Global Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Biologics and Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 24. North America Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 30. South America Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Vaccines
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • AbbVie
  • United Laboratory
  • Tonghua Dongbao
  • Sobi
  • Novo Nordisk
  • Kanghong Pharma
  • Innovent Biologics
  • Gan&Lee
  • Eli Lilly
  • Changchun High Tech
  • Celltrion
  • Biogen
  • Amgen
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biologics and Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biologics and Biosimilars Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biologics and Biosimilars Market Dynamics
  1. 2.1 Biologics and Biosimilars Industry Trends
  2. 2.2 Biologics and Biosimilars Industry Drivers
  3. 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biologics and Biosimilars Industry Restraints
3 Biologics and Biosimilars Market by Company
  1. 3.1 Global Biologics and Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Biologics and Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Biologics and Biosimilars Company Ranking (2024-2026)
  4. 3.4 Global Biologics and Biosimilars Company Manufacturing Base and Headquarters
  5. 3.5 Global Biologics and Biosimilars Company Product Type and Application
  6. 3.6 Global Biologics and Biosimilars Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biologics and Biosimilars Market by Type
  1. 4.1 Biologics and Biosimilars Type Introduction
  2. 4.1.1 Monoclonal Antibodies
  3. 4.1.2 Interferon
  4. 4.1.3 Insulin
  5. 4.1.4 Vaccines
  6. 4.1.5 Others
  7. 4.2 Global Biologics and Biosimilars Sales Value by Type
  8. 4.2.1 Global Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Biologics and Biosimilars Sales Value by Type (2021-2032)
  10. 4.2.3 Global Biologics and Biosimilars Sales Value Share by Type (2021-2032)
5 Biologics and Biosimilars Market by Application
  1. 5.1 Biologics and Biosimilars Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Biologics and Biosimilars Sales Value by Application
  6. 5.2.1 Global Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologics and Biosimilars Sales Value by Application (2021-2032)
  8. 5.2.3 Global Biologics and Biosimilars Sales Value Share by Application (2021-2032)
6 Biologics and Biosimilars Regional Value Analysis
  1. 6.1 Global Biologics and Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics and Biosimilars Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biologics and Biosimilars Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biologics and Biosimilars Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biologics and Biosimilars Sales Value (2021-2032)
  7. 6.3.2 North America Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biologics and Biosimilars Sales Value (2021-2032)
  10. 6.4.2 Europe Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biologics and Biosimilars Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biologics and Biosimilars Sales Value (2021-2032)
  16. 6.6.2 South America Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biologics and Biosimilars Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Biologics and Biosimilars Country-level Value Analysis
  1. 7.1 Global Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biologics and Biosimilars Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biologics and Biosimilars Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biologics and Biosimilars Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Biologics and Biosimilars Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Biologics and Biosimilars Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Biologics and Biosimilars Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Biologics and Biosimilars Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Biologics and Biosimilars Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 United Laboratory
  44. 8.8.1 United Laboratory Company Information
  45. 8.8.2 United Laboratory Business Overview
  46. 8.8.3 United Laboratory Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  47. 8.8.4 United Laboratory Biologics and Biosimilars Product Portfolio
  48. 8.8.5 United Laboratory Recent Developments
  49. 8.9 Tonghua Dongbao
  50. 8.9.1 Tonghua Dongbao Company Information
  51. 8.9.2 Tonghua Dongbao Business Overview
  52. 8.9.3 Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Tonghua Dongbao Biologics and Biosimilars Product Portfolio
  54. 8.9.5 Tonghua Dongbao Recent Developments
  55. 8.10 Sobi
  56. 8.10.1 Sobi Company Information
  57. 8.10.2 Sobi Business Overview
  58. 8.10.3 Sobi Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sobi Biologics and Biosimilars Product Portfolio
  60. 8.10.5 Sobi Recent Developments
  61. 8.11 Novo Nordisk
  62. 8.11.1 Novo Nordisk Company Information
  63. 8.11.2 Novo Nordisk Business Overview
  64. 8.11.3 Novo Nordisk Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
  66. 8.11.5 Novo Nordisk Recent Developments
  67. 8.12 Kanghong Pharma
  68. 8.12.1 Kanghong Pharma Company Information
  69. 8.12.2 Kanghong Pharma Business Overview
  70. 8.12.3 Kanghong Pharma Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Kanghong Pharma Biologics and Biosimilars Product Portfolio
  72. 8.12.5 Kanghong Pharma Recent Developments
  73. 8.13 Innovent Biologics
  74. 8.13.1 Innovent Biologics Company Information
  75. 8.13.2 Innovent Biologics Business Overview
  76. 8.13.3 Innovent Biologics Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Innovent Biologics Biologics and Biosimilars Product Portfolio
  78. 8.13.5 Innovent Biologics Recent Developments
  79. 8.14 Gan&Lee
  80. 8.14.1 Gan&Lee Company Information
  81. 8.14.2 Gan&Lee Business Overview
  82. 8.14.3 Gan&Lee Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Gan&Lee Biologics and Biosimilars Product Portfolio
  84. 8.14.5 Gan&Lee Recent Developments
  85. 8.15 Eli Lilly
  86. 8.15.1 Eli Lilly Company Information
  87. 8.15.2 Eli Lilly Business Overview
  88. 8.15.3 Eli Lilly Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Eli Lilly Biologics and Biosimilars Product Portfolio
  90. 8.15.5 Eli Lilly Recent Developments
  91. 8.16 Changchun High Tech
  92. 8.16.1 Changchun High Tech Company Information
  93. 8.16.2 Changchun High Tech Business Overview
  94. 8.16.3 Changchun High Tech Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
  96. 8.16.5 Changchun High Tech Recent Developments
  97. 8.17 Celltrion
  98. 8.17.1 Celltrion Company Information
  99. 8.17.2 Celltrion Business Overview
  100. 8.17.3 Celltrion Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Celltrion Biologics and Biosimilars Product Portfolio
  102. 8.17.5 Celltrion Recent Developments
  103. 8.18 Biogen
  104. 8.18.1 Biogen Company Information
  105. 8.18.2 Biogen Business Overview
  106. 8.18.3 Biogen Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Biogen Biologics and Biosimilars Product Portfolio
  108. 8.18.5 Biogen Recent Developments
  109. 8.19 Amgen
  110. 8.19.1 Amgen Company Information
  111. 8.19.2 Amgen Business Overview
  112. 8.19.3 Amgen Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Amgen Biologics and Biosimilars Product Portfolio
  114. 8.19.5 Amgen Recent Developments
  115. 8.20 3SBIO
  116. 8.20.1 3SBIO Company Information
  117. 8.20.2 3SBIO Business Overview
  118. 8.20.3 3SBIO Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  119. 8.20.4 3SBIO Biologics and Biosimilars Product Portfolio
  120. 8.20.5 3SBIO Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst